V451 vaccine
| Vaccine description | |
|---|---|
| Target disease | COVID-19 |
| Type | Subunit vaccine |
| Clinical data | |
| Other names | SARS-CoV-2 Sclamp |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status |
|
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 Portal |
V451 was a COVID-19 vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited. The vaccine candidate used the University of Queensland's molecular clamp technology,[1] and the MF59 adjuvant.[2]
Termination of development[edit]
The development of the vaccine was cancelled on 11 December 2020 after false-positive tests for HIV antibodies in a number of participants in the Phase I trial of the vaccine.[3][4] As part of the vaccine's design, researchers added "a fragment of one protein found on the HIV virus"[5] as a "ground-breaking molecular clamp technology"[6] which led to "a partial antibody response" to HIV and would have interfered with HIV screening tests.[7]
Nine days prior to the termination, on 2 December, the first emergency use authorisation was granted to a COVID-19 vaccine; the Pfizer–BioNTech COVID-19 vaccine in the United Kingdom.[8] Following the termination of V451, vaccine production capacity by CSL Limited was diverted to the Oxford–AstraZeneca COVID-19 vaccine.[9]
See also[edit]
References[edit]
- ^ "UQ-CSL V451 Vaccine". www.precisionvaccinations.com. Retrieved 2020-12-11.
- ^ Meneguzzi J (13 November 2020). "Why a COVID-19 vaccine could further imperil deep-sea sharks". National Geographic.
- ^ "Covid: Australian vaccine abandoned over false HIV response". BBC News. 2020-12-11. Retrieved 2020-12-11.
- ^ Reuters Staff (2020-12-10). "BRIEF-CSL Says Will Not Progress UQ-CSL V451 COVID-19 Vaccine Candidate To Phase 2/3 Clinical Trials". Reuters. Retrieved 2020-12-11.
- ^ Slezak, Michael (11 December 2020). "How the UQ coronavirus vaccine induced false-positive HIV test results and why scientists were prepared". ABC News.
- ^ Smyth J (11 December 2020). "Australia abandons local Covid vaccine over HIV test concerns". Financial Times.(subscription required)
- ^ "Australia ends local COVID vaccine trials due to HIV false positives". Deutsche Welle. 11 December 2020.
- ^ "UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 2 December 2020. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
- ^ "COVID-19 Update". www.csl.com. Retrieved 2021-01-31.
External links[edit]
- Clinical trial number NCT04495933 for "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults" at ClinicalTrials.gov
